A four-year experience with patient individualized heparin and protamine dosing using the hemochron® RxDx™ system

Journal of Extra-Corporeal Technology

Volumn 33, Issue 1, 2001, Pages 19-22

  Bennett, K M ^a   Briggins, D ^a   Zucker, M ^a   LaDuca, F ^a  

^a NONE   (United States)

Author keywords

Activated clotting time; Cardiac surgery; Hemochron RxDx

Indexed keywords

HEPARIN; PROTAMINE;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL PRACTICE; CONTROLLED STUDY; DEVICE; DOSE CALCULATION; DOSE RESPONSE; DRUG INFUSION; EMPIRICISM; EVALUATION; EXPERIENCE; FEMALE; HEART SURGERY; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RELIABILITY; TECHNIQUE; TREATMENT OUTCOME;

EID: 0035099811     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Protamine: A review of its toxicity
2. Anticoagulant activity in response to sequential heparin doses is nonlinear
3. Variability of effective anticoagulation for PTCA is dependent upon heparin potency
4. Heparin therapy during extracorporeal circulation: II-The use of a dose-response curve to individualize heparin and protamine dosage
5. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations
6. Heparin-protamine mismatch: A controllable factor in bleeding after open-heart surgery
7. Cost-effective management of heparin/protamine in CP bypass: Analysis by type of surgery